No profile data available.
Monopar Therapeutics Inc. (MNPR) is a healthcare company in the hepatic treatment pharmaceuticals industry, based in Wilmette, United States, with about 14 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$13.72 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $0. Its market capitalization was $531.06 million as of December 4, 2025.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of December 4, 2025.
, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States.
Monopar Therapeutics reported $0 in revenue for fiscal year 2025. In Q2 2026 revenue was $0.
$531.06 million as of December 4, 2025.
Listed companies of a similar size in the same industry (hepatic treatment pharmaceuticals) include Inventiva S.a. (IVA), Wave Life Sciences Ltd. (WVE), Sagimet Biosciences Inc. (SGMT), Galectin Therapeutics Inc. (GALT).